Insights for Clinicians: Leveraging Real-World Data for Informed Practice

1. Please discuss the limitations of current topical treatments for atopic dermatitis (AD), and in your view, how do these limitations impact patient management and QoL (Quality of Life)?

2. Can you describe the challenges faced by patients with AD in achieving adequate disease control with topical therapies?

3. How do non-steroidal formulations contribute to AD management, and what are their benefits?

4. Could you elaborate on the available topical therapy options and discuss the potential advantages they offer to patients?

5. What is the significance of ruxolitinib cream as a nonsteroidal monotherapy in the treatment of mild to moderate AD, especially considering the limitations of existing therapies?